Valeda is a Platform Utilizing Photobiomodulation to Deliver Specific Wavelengths to the Eye

The Valeda Light Delivery System is a breakthrough medical device designed for physicians dedicated to advancing the treatment of degenerative eye conditions.

Valeda delivers a non-invasive, multiwavelength, light-based therapy that utilizes photobiomodulation (PBM) to treat dry age-related macular degeneration (AMD) patients to improve vision.

Valeda’s targeted treatment addresses mitochondrial dysfunction in the retina, a key component of dry age-related macular degeneration (AMD), to improve visual acuity, reduce central drusen volume, and improve contrast sensitivity.

It’s Time for Patients to See Their Future

Valeda integrates seamlessly into clinical practice. Backed by extensive research and designed to optimize therapeutic benefits, Valeda is an essential addition for managing patients with dry age-related macular degeneration (AMD).

Valeda is the first photobiomodulation (PBM) device designed specifically for ophthalmic applications.

Valeda is the only photobiomodulation (PBM) device to be granted FDA de Novo authorization for medical claims associated with the treatment of dry age-related macular degeneration (AMD).

Treatments are delivered in a series of 9 sessions per eye over 3 – 5 weeks.

The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.

Now’s the Time to Talk

Request time with one of our representatives to learn more about Valeda.

Contact Us
Valeda